The METTL14‐YTHDF1‐SAP30 Axis Promotes Glycolysis and Oxaliplatin Resistance in Colorectal Adenocarcinoma via m6A Modification
Journal of Gastroenterology and Hepatology · 2025
DOI: 10.1111/jgh.16988 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2025. Verfasst von Haoran Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Oxaliplatin, Drug Resistance, Neoplasm, Glycolysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Guangzhou Science and Technology Program Project, Traditional Chinese Medicine Bureau of Guangdong Province.
Abstract (Originalsprache)
Colorectal cancer (CRC) is a prevalent cancer with a poor prognosis, especially in advanced metastatic stages. This study identifies SAP30 as a significantly upregulated gene in COAD, linking high SAP30 expression to reduced overall survival. Experimental validation revealed elevated SAP30 levels in CRC cell lines (SW480, RKO, HT29, and HCT15), with the highest expression in oxaliplatin‐resistant sublines (HT29‐OxR and HCT15‐OxR). SAP30 knockdown in oxaliplatin‐resistant cells reduced glycolytic activity, glucose consumption, and glycolytic enzyme expression (LDHA, HK1, HK2, GLUT1, and GLUT4), while SAP30 overexpression enhanced glycolysis, partially reversed by the GLUT1 inhibitor WZB117. SAP30 also promoted cell proliferation, inhibited apoptosis, and enhanced migration and invasion in resistant CRC cells. Mechanistically, METTL14, an m6A methyltransferase, upregulates SAP30 mRNA via m6A modification, stabilized by the m6A reader protein YTHDF1. This METTL14‐YTHDF1‐SAP30 axis sustains SAP30 expression, promoting glycolysis and oxaliplatin resistance. In vivo studies confirmed that SAP30 knockout impairs tumor growth and reduces proliferation and glycolysis markers. This study highlights the METTL14‐YTHDF1‐SAP30 axis in glycolysis and chemoresistance in CRC, suggesting SAP30 as a potential target to overcome oxaliplatin resistance and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
- Department of Hepatobiliary Pancreatic Hernia Surgery, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, China.
- Department of Infectious Disease, The First Affiliated Hospital of Jinan University, Guangzhou, China.
ORCID-Profile: Hailiang Li
Förderung
- Guangzhou Science and Technology Program Project
- Traditional Chinese Medicine Bureau of Guangdong Province
Zitieren
APA
Zhang, H., Wu, X., Nie, J., Li, X., Li, C., & Li, H. (2025). The METTL14‐YTHDF1‐SAP30 Axis Promotes Glycolysis and Oxaliplatin Resistance in Colorectal Adenocarcinoma via m6A Modification. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16988
Vancouver
Zhang H, Wu X, Nie J, Li X, Li C, Li H. The METTL14‐YTHDF1‐SAP30 Axis Promotes Glycolysis and Oxaliplatin Resistance in Colorectal Adenocarcinoma via m6A Modification. Journal of Gastroenterology and Hepatology. 2025. doi:10.1111/jgh.16988
BibTeX
@article{Zhang2025,
author = {Zhang, Haoran and Wu, Xunxin and Nie, Jinlin and Li, Xiaofeng and Li, Cheng and Li, Hailiang},
title = {The METTL14‐YTHDF1‐SAP30 Axis Promotes Glycolysis and Oxaliplatin Resistance in Colorectal Adenocarcinoma via m6A Modification},
journal = {Journal of Gastroenterology and Hepatology},
year = {2025},
doi = {10.1111/jgh.16988}
}
EUVIMED